Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
Part of paid clinical trials in New York, New York.
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Study ID
- NCT07675044
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Asthma
- Type 2 Asthma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- FeNO Breath Test — DIAGNOSTIC_TESTFractional Exhaled Nitric Oxide (FeNO) test breathing test that measures the amount of nitric oxide in exhaled breath to detect airway inflammation, aiding in the diagnosis and management of asthma
Study Details
This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- Jun 2026
- Primary completion
- May 31, 2027
- Completion
- May 31, 2027
Study Design
- Enrollment
- 200 participants (estimated)
Arms
- Arm: Participants with AsthmaIndividuals with a pre-existing diagnosis of asthma
Primary Outcome Measure
The proportion of patients with FeNO ≥ 25 ppb [ Time Frame: Day 1 ]
Central Contacts
- Jessica Harris, NP212-241-5656
- Linda Rogers, MD212-241-5656
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mount Sinai Health System | New York | New York | 10029 | Monica Kraft (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
Related Studies
- Registry of Asthma Characterization and Recruitment 3 (RACR3)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado
- BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled AsthmaRecruiting · Columbia University · Beacon, New York
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)PHASE3 · Recruiting · AstraZeneca · Mobile, Alabama
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPHASE3 · Recruiting · GlaxoSmithKline · Birmingham, Alabama